Coagulo is leading the evolution of personalized coagulation management with the introduction of the world’s first precision-medicine platform capable of pinpointing abnormalities across the entire clotting cascade and delivering clinically-valuable information that no other technology provides.

October 2021 - Coagulo is invited to present abstracts on the use of our coagulation test on hospitalized patients with COVID-19 at the 2022 Society of Critical Care Medicine Congress. September 2021 - Coagulo is invited to present results on the use of our new technology on anticoagulation assessment in hospitalized patients with COVID-19 at ...

Coagulo’s technology works with all direct and indirect Factor IIa and Xa inhibitors, including DOACs, and can also be used to detect the reversal of anticoagulation via the administration of bypassing agents or specific antidotes.

Coagulo’s products, including any in vitro diagnostic products referenced herein, are intended for investigational use only. They are not for commercial sale and are not for clinical diagnostic use.

Coagulo’s products, including any in vitro diagnostic products referenced herein, are intended for investigational use only. They are not for commercial sale and are not for clinical diagnostic use.

Coagulo is transforming medicine with the first portable and connected precision-medicine platform for smarter management of coagulation, enabling better healthcare outcomes for everyone. We do this by combining an entirely new set of patent-pending coagulation assays, cutting-edge microfluidic technology and proprietary data analytics and ...

Dr. Frydman has completed several fellowships at MIT, HMS and MGH, where she developed Coagulo’s platform technology. She has published numerous papers and book chapters on coagulation, platelet physiology, immunothrombosis and stem cell biology. Dr.

Coagulo’s products, including any in vitro diagnostic products referenced herein, are intended for investigational use only. They are not for commercial sale and are not for clinical diagnostic use.

Frydman has completed several fellowships at MIT, HMS and MGH, where she developed Coagulo’s platform technology. She has published numerous papers and book chapters on coagulation, platelet physiology, immunothrombosis and stem cell biology.

As pharmaceutical companies continue to develop new, more precise therapeutics for coagulation-related disorders, Coagulo will be right beside them, continuing to develop diagnostic and monitoring tools that harness the latest innovations to unlock the full capabilities of …